Dual versus triple antithrombotic therapy after percutaneous coronary intervention: the prospective multicentre WOEST 2 Study.
Autor: | Bor WL; Department of Cardiology, St. Antonius Hospital, Nieuwegein, the Netherlands., de Veer AJW; Department of Cardiology, St. Antonius Hospital, Nieuwegein, the Netherlands., Olie RH; Cardiovascular Research Institute Maastricht (CARIM), School for Cardiovascular Diseases, Maastricht University Medical Center, Maastricht, the Netherlands., Rikken SAOF; Department of Cardiology, St. Antonius Hospital, Nieuwegein, the Netherlands.; Cardiovascular Research Institute Maastricht (CARIM), School for Cardiovascular Diseases, Maastricht University Medical Center, Maastricht, the Netherlands., Chan Pin Yin DRPP; Department of Cardiology, St. Antonius Hospital, Nieuwegein, the Netherlands., Herrman JPR; Department of Cardiology, OLVG Hospital, Amsterdam, the Netherlands., Vrolix M; Department of Cardiology, Ziekenhuis Oost-Limburg, Genk, Belgium., Meuwissen M; Department of Cardiology, Amphia Hospital, Breda, the Netherlands., Vandendriessche T; Department of Cardiology, Antwerp University Hospital, Edegem, Belgium., van Mieghem C; Cardiovascular Research Center Aalst, OLV Clinic, Aalst, Belgium.; Department of Cardiology, AZ Groeninge, Kortrijk, Belgium., Magro M; Department of Cardiology, Elisabeth-TweeSteden Hospital, Tilburg, the Netherlands., Bennaghmouch N; Department of Cardiology, St. Antonius Hospital, Nieuwegein, the Netherlands., Hermanides R; Department of Cardiology, Isala Hospital, Zwolle, the Netherlands., Adriaenssens T; Department of Cardiovascular Medicine, University Hospitals Leuven, Leuven, Belgium., Dewilde WJM; Department of Cardiology, Belgium Imelda Hospital, Bonheiden, Belgium., Ten Berg JM; Department of Cardiology, St. Antonius Hospital, Nieuwegein, the Netherlands.; Cardiovascular Research Institute Maastricht (CARIM), School for Cardiovascular Diseases, Maastricht University Medical Center, Maastricht, the Netherlands. |
---|---|
Jazyk: | angličtina |
Zdroj: | EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology [EuroIntervention] 2022 Jul 22; Vol. 18 (4), pp. e303-e313. Date of Electronic Publication: 2022 Jul 22. |
DOI: | 10.4244/EIJ-D-21-00703 |
Abstrakt: | Background: For patients on oral anticoagulants (OAC) undergoing percutaneous coronary intervention (PCI), European guidelines have recently changed their recommendations to dual antithrombotic therapy (DAT; P2Y Aims: The prospective WOEST 2 registry was designed to obtain contemporary real-world data on antithrombotic regimens and related outcomes after PCI in patients with an indication for OAC. Methods: In this analysis, we compare DAT (P2Y Results: A total of 1,075 patients were included between 2014 and 2021. Patients used OAC for atrial fibrillation (93.6%) or mechanical heart valve prosthesis (4.7%). Non-vitamin K oral anticoagulants (NOAC) were prescribed in 53.1% and vitamin K antagonists in 46.9% of patients. At discharge, 60.9% received DAT, and 39.1% TAT. DAT was associated with less clinically relevant and similar major bleeding (16.8% vs 23.4%; p<0.01 and 7.6% vs 7.7%, not significant), compared to TAT. The difference in MACCE between the two groups was not statistically significant (12.4% vs 9.7%; p=0.17). Multivariable adjustment and propensity score matching confirmed these results. Conclusions: Dual antithrombotic therapy is associated with a substantially lower risk of clinically relevant bleeding without a statistically significant penalty in ischaemic events. |
Databáze: | MEDLINE |
Externí odkaz: |